Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

inherent in the Orexigen business, including, without limitation: the clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; the potential that earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Refo
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... , April 23, 2015 /PRNewswire/ - Crystal Research Associates, ... Informational Overview ® (EIO) on Aeterna Zentaris Inc. ... is available on Crystal Research Associates, website at ... Zentaris, website at www.aezsinc.com . Aeterna ... specialty biopharmaceutical company in oncology, endocrinology, and women,s health. ...
(Date:4/22/2015)... , April 22, 2015  Sangamo BioSciences, Inc. ... 2015 financial results and accomplishments. For the ... consolidated net loss of $5.3 million, or $0.08 per ... or $0.12 per share, for the same period in ... cash, cash equivalents, marketable securities and interest receivable of ...
(Date:4/22/2015)... April 22, 2015 Steep Hill, the ... today that it has opened an investment round ... and expansion.  The common stock investment round will ... a law intended to encourage funding of small ... 506(c), small businesses largely relied on friends and ...
Breaking Biology Technology:Glemser Earns Accreditation for Life Sciences Solution Suite 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Agreement Enables Spherix to Pursue All Pharmaceutical and Health-Oriented ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has terminated the 1996 license agreement pursuant to ...
... SAO PAULO, June 23 What does sugarcane have ... successful,30-year experience with sugarcane as a feedstock for ethanol. In ... replace a fossil fuel with,renewable energy has saved some 600 ... years for six billion trees to achieve the same,results. , ...
... , Continuing Supplies Will Be Used For NDA and ... Type 2 Diabetes , , BETHESDA, Md., June ... an innovator in biotechnology for diabetes therapy, and a ... supplement, biotechnology and pharmaceutical companies, today announced that it ...
Cached Biology Technology:Spherix Announces Termination of Arla License Agreement 2Spherix Announces Termination of Arla License Agreement 3Spherix Announces Termination of Arla License Agreement 4Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 3Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 4Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... NT APRIL 2010 High in the Mackenzie Mountains, ... being revealed as warming temperatures melt patches of ice that ... Tom Andrews, an archaeologist with the Prince of Wales Northern ... Polar Year Ice Patch Study, is amazed at the implements ...
... April 26, 2010 Energy in, energy out, it,s the ... more than two thirds of Americans classified as overweight or ... Journal of Nutrition Education and Behavior examines how ... loss programs. Researchers at the University of Kentucky and ...
... 26 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader ... (OK) Sheriff,s Office successful deployment of an FBI-compliant advanced authentication solution for ... authentication. , , , ... http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , , , ...
Cached Biology News:Ancient artifacts reveals as northern ice patches melt 2What's motivation got to do with weight loss? 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 2BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 3BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders 4
ID clarifier: With ethidium bromide (50 μg/ml)...
... Propidium Iodide (PI) is a fluorescent ... double-stranded nucleic acids. As a nuclear ... to dark red in color. The ... green or blue fluorochromes such as FITC, ...
... were cultured in DMEM and harvested at the ... keep the antigens in their native forms, cells ... arrayed on a 12-well (5 mm) adhesive coated ... enhance cellular attachment and to minimize background staining. ...
...
Biology Products: